| Biotechnology Industry | Healthcare Sector | Kim Kelderman CEO | B3 Exchange | - ISIN |
| US Country | 3,100 Employees | - Last Dividend | 30 Nov 2022 Last Split | 9 Feb 1989 IPO Date |
Bio-Techne Corporation operates at the forefront of the life science sector, providing a comprehensive range of products and services crucial for research, clinical diagnostics, and therapeutic development. With a global footprint, the company serves a diverse clientele spread across the United States, the United Kingdom, rest of Europe, Middle East, Africa, Greater China, and the rest of the Asia-Pacific region. Bio-Techne is structured into two main operational segments: Protein Sciences, and Diagnostics and Genomics, each addressing different needs within the life sciences and diagnostics sectors. Originally established in 1976 under the name Techne Corporation, the organization underwent a rebranding to Bio-Techne Corporation in November 2014 and is based in Minneapolis, Minnesota. This strategic evolution reflects its broadened focus beyond its initial scope, signaling its expansion into a comprehensive suite of technologies and services catering to the dynamic requirements of biological research and clinical diagnostics.
Bio-Techne Corporation distinguishes itself through its broad portfolio of products and services across two main segments: